Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report

Neurotrophic keratopathy is a potential consequence of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection. The treatment is based on artificial tears and the withdrawal of preserved eye drops or other types of epitheliotoxic topical medicines. Autologous serum or amniotic membrane...

Full description

Saved in:
Bibliographic Details
Published inJournal francais d'ophtalmologie Vol. 35; no. 3; p. 187.e1
Main Authors De Monchy, I, Labbé, A, Pogorzalek, N, Gendron, G, M'Garrech, M, Kaswin, G, Labetoulle, M
Format Journal Article
LanguageFrench
Published France 01.03.2012
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Neurotrophic keratopathy is a potential consequence of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection. The treatment is based on artificial tears and the withdrawal of preserved eye drops or other types of epitheliotoxic topical medicines. Autologous serum or amniotic membrane transplantation may also be used in severe cases, but their cost and safety are still under debate. We report a case of a patient with a history of herpes zoster ophthalmicus, who developed a persistent epithelial ulcer after cataract surgery, with no improvement despite 3 weeks of artificial tears (eight drops per day). A new ophthalmologic solution based on a regenerating agent (RGTA, Cacicol20(®)) was then used, with a dosage of two eye drops per week for 6 weeks. Improvement was observed 1 week later, and complete healing was obtained in less than 3 weeks, with no side effects. This heparin mimetic, which may stimulate extracellular matrix healing, may be a possible alternative therapy to autologous serum or amniotic membrane transplantation in severe neurotrophic ulcer. However, randomized studies are necessary to validate this observation.
AbstractList Neurotrophic keratopathy is a potential consequence of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection. The treatment is based on artificial tears and the withdrawal of preserved eye drops or other types of epitheliotoxic topical medicines. Autologous serum or amniotic membrane transplantation may also be used in severe cases, but their cost and safety are still under debate. We report a case of a patient with a history of herpes zoster ophthalmicus, who developed a persistent epithelial ulcer after cataract surgery, with no improvement despite 3 weeks of artificial tears (eight drops per day). A new ophthalmologic solution based on a regenerating agent (RGTA, Cacicol20(®)) was then used, with a dosage of two eye drops per week for 6 weeks. Improvement was observed 1 week later, and complete healing was obtained in less than 3 weeks, with no side effects. This heparin mimetic, which may stimulate extracellular matrix healing, may be a possible alternative therapy to autologous serum or amniotic membrane transplantation in severe neurotrophic ulcer. However, randomized studies are necessary to validate this observation.
Author De Monchy, I
Kaswin, G
Gendron, G
Labetoulle, M
M'Garrech, M
Labbé, A
Pogorzalek, N
Author_xml – sequence: 1
  givenname: I
  surname: De Monchy
  fullname: De Monchy, I
  organization: Service d'ophtalmologie, CHU Bicêtre, Assistance publique-Hôpitaux de Paris, 78, avenue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
– sequence: 2
  givenname: A
  surname: Labbé
  fullname: Labbé, A
– sequence: 3
  givenname: N
  surname: Pogorzalek
  fullname: Pogorzalek, N
– sequence: 4
  givenname: G
  surname: Gendron
  fullname: Gendron, G
– sequence: 5
  givenname: M
  surname: M'Garrech
  fullname: M'Garrech, M
– sequence: 6
  givenname: G
  surname: Kaswin
  fullname: Kaswin, G
– sequence: 7
  givenname: M
  surname: Labetoulle
  fullname: Labetoulle, M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22015067$$D View this record in MEDLINE/PubMed
BookMark eNo1j9FKwzAUhoMobs49gDeSS71oPUmbpfVuDJ3CRJB5PdL2ZOtYm5Ck6Hx6I-rVB-f8_8c5F-S0Nz0ScsUgZcBmd_t0r03KgbEUyhSAn5AxkzJLQJRyRKbetxWwcsalEOycjHiMCpjJMcEX1astdtgHajTdobPo6ZfxAR3tcXAmOGN3bU2HQx1Hg2_7LVVx9UE7FVz7SUMsKXukURMlN2_L9fz2ns5prTxSh9a4cEnOtDp4nP5xQt4fH9aLp2T1unxezFeJZTmEpBQ8YwiiyDNZ1LwSUiqQhf45VZZZLoSukTdNBECGCptCIeRC50WVVxr4hFz_eu1QddhsrGs75Y6b_3_5NyajWPI
ContentType Journal Article
Copyright Copyright © 2011 Elsevier Masson SAS. All rights reserved.
Copyright_xml – notice: Copyright © 2011 Elsevier Masson SAS. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1016/j.jfo.2011.09.002
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
DocumentTitleAlternate Utilisation d'un agent biodégradable de la régénération tissulaire (RGTA) dans le traitement d'un ulcère trophique résistant d'origine zostérienne : à propos d'un cas
EISSN 1773-0597
ExternalDocumentID 22015067
Genre English Abstract
Journal Article
Case Reports
GroupedDBID ABJNI
ALMA_UNASSIGNED_HOLDINGS
CGR
CUY
CVF
ECM
EIF
NPM
ID FETCH-LOGICAL-p140t-95231e0584378c2b577a078f5067793455fce2dd5fc003eaed8ae045f48b4bf02
IngestDate Fri Feb 23 03:05:33 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 3
Language French
License Copyright © 2011 Elsevier Masson SAS. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p140t-95231e0584378c2b577a078f5067793455fce2dd5fc003eaed8ae045f48b4bf02
PMID 22015067
ParticipantIDs pubmed_primary_22015067
PublicationCentury 2000
PublicationDate 2012-Mar
PublicationDateYYYYMMDD 2012-03-01
PublicationDate_xml – month: 03
  year: 2012
  text: 2012-Mar
PublicationDecade 2010
PublicationPlace France
PublicationPlace_xml – name: France
PublicationTitle Journal francais d'ophtalmologie
PublicationTitleAlternate J Fr Ophtalmol
PublicationYear 2012
SSID ssib019627551
ssib053390985
Score 2.0410087
Snippet Neurotrophic keratopathy is a potential consequence of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection. The treatment is based on...
SourceID pubmed
SourceType Index Database
StartPage 187.e1
SubjectTerms Administration, Ophthalmic
Aged, 80 and over
Anti-Ulcer Agents - administration & dosage
Anti-Ulcer Agents - therapeutic use
Corneal Ulcer - drug therapy
Corneal Ulcer - etiology
Glycosaminoglycans - administration & dosage
Herpes Zoster - complications
Herpes Zoster - drug therapy
Herpes Zoster Ophthalmicus - complications
Herpes Zoster Ophthalmicus - drug therapy
Humans
Male
Ophthalmic Solutions - administration & dosage
Optic Nerve Diseases - drug therapy
Optic Nerve Diseases - etiology
Regeneration - drug effects
Regeneration - physiology
Title Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report
URI https://www.ncbi.nlm.nih.gov/pubmed/22015067
Volume 35
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swGBVp97KX0tJdeht66KDDOCSOHdl7C10vjFFKSaFvRZKlXlMbN2Fbfkh_b48ku3ZCxra-OEYydqzv-NPRdxMhuwwcgadR7EdaSj_kUvixTrifBB2h0pD1uLIBsif94_Pw-0V00Wo9NaKWJmPRltOFeSWvkSraIFeTJfsfkn25KRpwDvniCAnj-E8yrmNXHOcrcvXoTU3aRuHZQpXjIsuvb6Q3uZdomli7ADe7iHsjU5r_l-fSr357_KosPXp2NBx8DhKXsC4xxZVehUUkVptNOfjNo4f3ZngQePzI6tIXsHyzSkNez9pnf3AhnIN-xph6ml1lxRQT1t2Mi8hsdle42ICjpo3CBHtUQVpt5fQqYyZM0IXiVorX1SkpAdZraNFuzNqqu1DBO1vDbftWZ2X9VVNvNGheixHKR1biQWALKLK_987V3K66lsgSi432PKltQF2zXVFU-1LBl5NOEkeVy9wGD879PVNyurzl3PLF0pjhKlkpRUcHDkxrpKWLdaJqINFMUwck6oBEm0CiFkjUAolydP2kDki0BBK1QKJ7BkZfvtIBNRCiDkLvyPnhwXD_2C_33_BzLLvHfhKB_KsOKGqPxTIQEWMcjFKb14BaDyN83ypIU_xgblBcpTFXWCLoMBah0J3gPVl-yB7UR0KVSRbqgy9qJcJQ97lIwVsluLfA-oP3NsgHNyqXuSuyclmN1-Yfe7bI2xpr2-SNxletdkARx-KTldgzDiBiag
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Management+of+herpes+zoster+neurotrophic+ulcer+using+a+new+matrix+therapy+agent+%28RGTA%29%3A+A+case+report&rft.jtitle=Journal+francais+d%27ophtalmologie&rft.au=De+Monchy%2C+I&rft.au=Labb%C3%A9%2C+A&rft.au=Pogorzalek%2C+N&rft.au=Gendron%2C+G&rft.date=2012-03-01&rft.eissn=1773-0597&rft.volume=35&rft.issue=3&rft.spage=187.e1&rft_id=info:doi/10.1016%2Fj.jfo.2011.09.002&rft_id=info%3Apmid%2F22015067&rft_id=info%3Apmid%2F22015067&rft.externalDocID=22015067